Cullinan Therapeutics

Today, we shared positive updated results from our pivotal Phase 2b REZILIENT1 trial in patients receiving zipalertinib after prior treatment with amivantamab at ESMO - European Society for Medical Oncology Congress. We also shared that enrollment of this trial has been completed ahead of schedule. Learn more: https://bit.ly/4e2yk7A ? #ESMO24?

While cytokines play a key role in immune system activation, clinical adoption of cytokine-based therapies for the treatment of cancer has been limited due to low response rates and severe toxicities. ? ? In a perspective piece in Frontiers in Oncology, our scientists discuss the potential of intratumoral delivery of cytokines optimized for tumor retention as a therapeutic solution that may address these limitations. ? ? We’re investigating the clinical potential of this approach with CLN-617, a collagen-binding fusion protein, that co-delivers IL-2 and IL-12 on a single molecule.? ? Read the full perspective: https://bit.ly/4716RjO?? ? #Immunotherapy #CancerResearch #FrontiersInOncology ?

Our team maintains an unrelenting focus to fulfill our purpose?of bringing new standards of care to patients by staying at the cutting edge of research. ? ? We look forward to seeing the latest emerging science in oncology at #ESMO24 and contributing to this important opportunity for scientific exchange.? ? On September 14 at 10:15 a.m. CEST, we will be sharing a mini oral presentation of updated findings for our lead investigational candidate in non-small cell lung cancer patients with insertions at exon 20. Learn more: https://bit.ly/4d1jtc9

Today at 4:05 PM ET, Nadim Ahmed, President and CEO, and Jeff Jones, Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference.?? ? A live webcast and recording will be available here: https://bit.ly/4bD5WHU ?

#BloodCancerAwarenessMonth is held every September to raise awareness of blood cancers, which affect the bone marrow, blood cells, lymph nodes, and other parts of the lymphatic system. Our team is advancing clinical research that may bring new standards of care to people living with relapsed and refractory #MultipleMyeloma and acute myeloid #leukemia (AML). https://bit.ly/3Xghixd

We’re pleased to welcome Sznol Mario, MD to our Scientific Advisory Board. Dr. Sznol has extensive experience in cancer immunotherapy and drug development in oncology. His background includes more than a decade in the Biologics Evaluation Section (BES), Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program of the National Cancer Institute and 20 years as part of the medical oncology faculty at Yale. Dr. Sznol is currently a professor of internal medicine and co-leader of the Cancer Immunology Program at the Yale Comprehensive Cancer Center where he focuses on early drug development, immunotherapy, and treatments for advanced melanoma and kidney cancer. Dr. Sznol’s expertise will be invaluable as we continue to advance our diverse pipeline through clinical development. https://bit.ly/4amtj6W

The team enjoyed a perfect break from the workday by spending an afternoon kayaking on the Charles River. With plenty of sunshine, it was the ideal way to relax and recharge as summer winds down. A big thank you to everyone who helped organize and joined in on such a fun afternoon!

We’re proud to announce the opening of the first clinical trial site for the evaluation of CLN-619, our novel anti-MICA/B antibody, in patients with relapsed and refractory multiple myeloma.?? ? We’re grateful for clinical site partners who help us advance research to bring new potential treatment options to patients.?https://bit.ly/4cKU1Ya

An overactive immune response, driven by B cells and/or T cells, may contribute to the pathogenesis of autoimmune diseases. So, what does that mean for CD19 and T cell engagers?? ? CD19 is a cell surface receptor that is broadly expressed on all B cells. T cell engagers are protein constructs engineered to redirect the immune system’s T cells to eliminate cells expressing a specific cell surface target, such as CD19 on B cells.?? ? T cell engagers offer a convenient off-the-shelf therapeutic option that may enhance patient convenience, reduce toxicity, and improve overall efficacy.?? ? Explore our fact sheet to learn more about CD19 and T cell engagers in autoimmune diseases.?https://bit.ly/3MdGPAk ? #TCellEngagers #AutoImmuneDisease #Immunology?

Dysregulation of the immune system, particularly driven by B cells or T cells, may play a key role in both cancer and autoimmune disorders. ? ? Jennifer Michaelson, our Chief Scientific Officer, explores the potential of leveraging T cell-mediated targeted therapies in autoimmune diseases and how we’re harnessing high-impact targets with the most effective modality to address unmet patient needs. Read her full article. https://bit.ly/4fLjNyt